 The magnitude of this reflected pressure wave can be quantified by the augmentation index AIx. The use of vasoactive agents which antagonize this increase in late systolic load and AIx may prove useful in the treatment of heart failure, by facilitating cardiac ejection during late systole when reflected pressure waves predominate. However, it has never been conclusively shown in humans that CBP-targeted therapy is useful in the management of HF. 